Page 109 - Read Online

Franco et al. Hepatoma Res 2018;4:74 I http://dx.doi.org/10.20517/2394-5079.2018.94 Page 13 of 18

containing DAA regimens: results of the retreatment study. Available from: http://www.natap.org/2016/EASL/EASL_11.htm. [Last
accessed on 28 Nov 2018]
43. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV
infection. N Engl J Med 2017;376:2134-46.
44. AASLD/IDSA. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic
HCV genotype 1 infection [Abstract 253]. Available from: https://www.hcvguidelines.org/references/zeuzem-2016. [Last accessed on
28 Nov 2018]
45. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C
virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017;66:389-97.
46. Poordad F, Pol S, Asatryan A, Buti M, Shaw DR, et al. MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in
patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Gastroenterology 2017;152:S1057.
47. Rice CM, Saeed M. Hepatitis C: treatment triumphs. Nature 2014;510:43-4.
48. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis
in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
49. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of
hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
50. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, et al. Association between sustained virological response and all-cause
mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
51. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Sustained virologic response and clinical outcomes in patients
with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84.
52. Johnson RJ, Gretch DR, Couser WG, Alpers CE, Wilson J, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-
interferon therapy. Kidney Int 1994;46:1700-4.
53. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, et al. Sustained virological response reduces incidence of onset of type 2
diabetes in chronic hepatitis C. Hepatology 2009;49:739-44.
54. Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin
lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol
1995;22:249-50.
55. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and
treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
56. Jézéquel C, Bardou-Jacquet E, Desille Y, Renard I, Lainé F, et al. Survival of patients infected by chronic hepatitis C and F0F1 fibrosis
at baseline after a 15 year follow-up. J Hepatol 2015;62:S589.
57. Øvrehus ALH, Blach S, Christensen PB, Gerstoft J, Weis N, et al. Impact of prioritizing treatment in a high resource setting -
minimizing the burden of HCV related disease in 15 years. J Hepatol 2015;62:S591-2.
58. CROI. Impact of deferring HCV treatment on liver-related events in HIV+ patients. Available from: http://www.croiconference.org/
sessions/impact-deferring-hcv-treatment-liver-related-events-hiv-patients. [Last accessed on 28 Nov 2018]
59. Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, et al. Effects of viral eradication with ledipasvir and sofosbuvir, with or without
ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol.2016;14:15 -64.
60. Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection:
insights from a work productivity economic model from the United States. Hepatology 2015;61:1471-8.
61. Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in
patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis 2015;212:367-77.
62. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, et al. Health-related quality of life in patients with chronic
hepatitis C and advanced fibrosis. J Hepatol 2007;46:420-31.
63. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-
related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
64. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts).
Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study
group on hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-40.
65. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV
therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
66. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on
mortality in patients with advanced liver disease. Hepatology 2017; doi: 10.1002/hep.29408.
67. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with
HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis 2013;207:S19-25.
68. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.
Harm Reduct J 2013;10:7.
69. Wolfe D, Luhmann N, Harris M, Momenghalibaf A, Albers E, et al. Human rights and access to hepatitis C treatment for people who
inject drugs. Int J Drug Policy 2015;26:1072-80.
70. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, et al. Treatment of hepatitis C virus infection among people who are
actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013;57:S80-9.
71. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving
opioid agonist therapy: a randomized trial. Ann Intern Med 2016;165:625-34.
72. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with